Education
About Us
Working with TipRanks
Follow Us
Prestige Consumer Healthcare (PBH)
NYSE:PBH
PBH Stock Chart & Stats
$59.58
-$0.15(-0.20%)
At close: 4:00 PM EST
$59.58
-$0.15(-0.20%)
Day’s Range― - ―
52-Week Range$57.25 - $90.04
Previous CloseN/A
Volume57.25K
Average Volume (3M)425.23K
Market Cap
$2.86B
Enterprise Value$4.00B
Total Cash (Recent Filing)$119.11M
Total Debt (Recent Filing)$1.04B
Price to Earnings (P/E)14.8
Beta0.33
Next Earnings
Feb 05, 2026EPS Estimate
1.14Last Dividend Ex-Date
Sep 27, 2018Dividend YieldN/A
Share Statistics
EPS (TTM)1.07
Shares Outstanding48,084,010
10 Day Avg. Volume436,980
30 Day Avg. Volume425,231
Financial Highlights & Ratios
PEG Ratio7.62
Price to Book (P/B)2.33
Price to Sales (P/S)3.76
P/FCF Ratio17.56
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue3.60
Enterprise Value/Gross Profit6.38
Enterprise Value/Ebitda11.20
Forecast
1Y Price Target
$77.75Price Target Upside30.50% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)4.55
Revenue Forecast (FY)$1.11B
Bulls Say, Bears Say
Bulls Say
Earnings Exceed ExpectationsSales and earnings exceeded expectations due to Clear Eyes supply timing and the timing of certain retailer orders.
Share Repurchases And ValuationWith leverage low, Prestige bought back 1.6 million shares for $110 million year-to-date, with cumulative free cash flow generation on track to be about $1 billion over the next four years, it has ample capacity to do more.
Strong Free Cash FlowManagement reiterated strong free cash flow of $245M+ for the fiscal year.
Bears Say
North America Sales DeclineNorth America sales were down 3.8% driven by continued eye care constraints.
Organic Sales DeclineOrganic sales declined 3% due to anticipated supply constraints, but this was better than expected given help from the timing of Clear Eyes supply and accelerated e-commerce orders that were above consumption.
Sales WeaknessSales weakness is noted while the company works to get their eye care supply back online.
Prestige Consumer Healthcare News
PBH FAQ
What was Prestige Consumer Healthcare’s price range in the past 12 months?
Prestige Consumer Healthcare lowest stock price was $57.25 and its highest was $90.04 in the past 12 months.
What is Prestige Consumer Healthcare’s market cap?
Prestige Consumer Healthcare’s market cap is $2.86B.
When is Prestige Consumer Healthcare’s upcoming earnings report date?
Prestige Consumer Healthcare’s upcoming earnings report date is Feb 05, 2026 which is in 67 days.
How were Prestige Consumer Healthcare’s earnings last quarter?
Prestige Consumer Healthcare released its earnings results on Nov 06, 2025. The company reported $1.07 earnings per share for the quarter, beating the consensus estimate of $0.97 by $0.1.
Is Prestige Consumer Healthcare overvalued?
According to Wall Street analysts Prestige Consumer Healthcare’s price is currently Undervalued.
Does Prestige Consumer Healthcare pay dividends?
Prestige Consumer Healthcare pays a Notavailable dividend of $0.475 which represents an annual dividend yield of N/A. See more information on Prestige Consumer Healthcare dividends here
What is Prestige Consumer Healthcare’s EPS estimate?
Prestige Consumer Healthcare’s EPS estimate is 1.14.
How many shares outstanding does Prestige Consumer Healthcare have?
Prestige Consumer Healthcare has 48,084,010 shares outstanding.
What happened to Prestige Consumer Healthcare’s price movement after its last earnings report?
Prestige Consumer Healthcare reported an EPS of $1.07 in its last earnings report, beating expectations of $0.97. Following the earnings report the stock price went up 2.557%.
Which hedge fund is a major shareholder of Prestige Consumer Healthcare?
Currently, no hedge funds are holding shares in PBH
Prestige Consumer Healthcare Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$77.75 (30.50% Upside)
$77.75 (30.50% Upside)
Blogger Sentiment
Bullish
PBH Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $178.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.37%
12-Months-Change
Fundamentals
Return on Equity
11.29%
Trailing 12-Months
Asset Growth
3.78%
Trailing 12-Months
Company Description
Prestige Consumer Healthcare
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
PBH Company Deck
PBH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted strong growth in e-commerce and effective cost management, along with successful market share expansion in the dental category. However, challenges with Clear Eyes supply constraints and declining revenue due to lower sales in key categories were noted. Investment in marketing and strategic acquisitions are expected to support future growth.View all PBH earnings summariesPBH Stock 12 Month Forecast
Average Price Target
$77.75
▲(30.50% Upside)
Technical Analysis
Cardinal Health
―
Henry Schein
―
McKesson
―
Owens & Minor
―
Guardian Pharmacy Services, Inc. Class A
―
Ownership Overview
Currently, No data available
---